Winny Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Winny Yan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aysegül Ilhan-Mutlu
Department of Medicine 1, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Dagmar Kollmann
Department of General Surgery, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Gerd Jomrich
Department of General Surgery, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Hannah Christina Puhr
Department of Medicine 1, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Reza Asari
Department of General Surgery, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Sebastian Friedrich Schoppmann
Department of General Surgery, Gastroesophageal Tumor Unit-Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria
3 shared publications
Latest Publications
- Open Access
Associations Between FGF8, FGF18, and FGFR4 Expression and Immune Checkpoint Markers PD-1 and PD-L1 in Adenocarcinoma of the Gastroesophageal Junction (AEG)
Background: Adenocarcinoma of the esophagogastric junction (AEG) remains a highly lethal disease despite multimodal therapy. The interplay between fibroblast growth factor (FGF) signaling and immune-checkpoint regulation in AEG is poorly understood. This study investigated the associations between FGF8, FGF18, and FGFR4 expression and PD-1/PD-L1/PD-L2 expression. Methods: In a cohort of 117 resected AEG cases, immunohistochemical expression of FGF8, FGF18, PD-1, PD-L1, and PD-L2 was analyzed. Associations were assessed using chi-square tests and Pearson correlation analyses. Combined FGF8–FGF18 expression groups and survival outcomes were evaluated using Kaplan–Meier analysis. Results: The updated correlation analysis included 107 cases and identified a weak inverse association between FGF8 expression and PD-L1 expression in tumor cells (r = −0.175, p = 0.036). No statistically significant correlations were observed between FGF18 expression and the investigated immune-checkpoint markers. Clinically, FGF18 was associated with advanced pT stage (p < 0.001) and postoperative UICC classification (p = 0.005), while both FGF8 (p = 0.022) and FGF18 (p = 0.015) were associated with lymph node metastasis. In the combined FGF8–FGF18 analysis, PD-1-negative lymphocytes occurred exclusively in the low-FGF8/low-FGF18 group (p = 0.042). Kaplan–Meier analysis demonstrated significantly poorer survival in FGF8-high tumors (p < 0.001). Conclusions: FGF8 was associated with poorer overall survival and showed a weak inverse association with PD-L1 expression in tumor cells. FGF18 was not significantly correlated with the investigated immune-checkpoint markers. The association between combined FGF8–FGF18 expression patterns and PD-1 positivity in lymphocytes warrants further investigation.
Open AccessAssociations Between FGF8, FGF18, and FGFR4 Expression and Immune Checkpoint Markers PD-1 and PD-L1 in Adenocarcinoma of the Gastroesophageal Junction (AEG)
Background: Adenocarcinoma of the esophagogastric junction (AEG) remains a highly lethal disease despite multimodal therapy. The interplay between fibroblast growth factor (FGF) signaling and immune-checkpoint regulation in AEG is poorly understood. This study investigated the associations between FGF8, FGF18, and FGFR4 expression and PD-1/PD-L1/PD-L2 expression. Methods: In a cohort of 117 resected AEG cases, immunohistochemical expression of FGF8, FGF18, PD-1, PD-L1, and PD-L2 was analyzed. Associations were assessed using chi-square tests and Pearson correlation analyses. Combined FGF8–FGF18 expression groups and survival outcomes were evaluated using Kaplan–Meier analysis. Results: The updated correlation analysis included 107 cases and identified a weak inverse association between FGF8 expression and PD-L1 expression in tumor cells (r = −0.175, p = 0.036). No statistically significant correlations were observed between FGF18 expression and the investigated immune-checkpoint markers. Clinically, FGF18 was associated with advanced pT stage (p < 0.001) and postoperative UICC classification (p = 0.005), while both FGF8 (p = 0.022) and FGF18 (p = 0.015) were associated with lymph node metastasis. In the combined FGF8–FGF18 analysis, PD-1-negative lymphocytes occurred exclusively in the low-FGF8/low-FGF18 group (p = 0.042). Kaplan–Meier analysis demonstrated significantly poorer survival in FGF8-high tumors (p < 0.001). Conclusions: FGF8 was associated with poorer overall survival and showed a weak inverse association with PD-L1 expression in tumor cells. FGF18 was not significantly correlated with the investigated immune-checkpoint markers. The association between combined FGF8–FGF18 expression patterns and PD-1 positivity in lymphocytes warrants further investigation.
- Open Access
Lymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification
Adenocarcinoma of the gastroesophageal junction (AEG) is an aggressive cancer with rising incidence and poor long-term survival despite multimodal treatment. Reliable preoperative prognostic markers are lacking. Methods: The study is based on data from a prospectively maintained institutional database, which was retrospectively analyzed. In total, 211 patients were analyzed who underwent curative resection for AEG to evaluate the association of SII and LVI and their combined prognostic value. Results: LVI was present in 45% of patients and was significantly associated with higher median SII values compared to patients without LVI (943 vs. 652; p < 0.001). Both high SII and the presence of LVI were independently associated with worse overall survival (p < 0.001 for both). In patients treated with primary surgery (65%), the combined presence of high SII and LVI identified a subgroup with particularly poor prognosis (pseudo-R2 increased from 0.451 to 0.524; likelihood-ratio test p < 0.001). Among patients who received neoadjuvant therapy (NT) (35%), SII remained a strong prognostic factor (pseudo-R2 = 0.432), while LVI alone was not statistically significant (p = 0.135), and its addition to the SII model did not improve prognostic performance (p = 0.377). Conclusions: The combined assessment of SII and LVI may improve prognostic stratification in AEG, especially in patients undergoing upfront surgery. These findings suggest that combined assessment of SII and LVI enhances prognostic stratification, particularly in patients treated with upfront surgery, and may aid personalized treatment and follow-up planning in AEG. To the best of our knowledge, this is the first study investigating the association of SII and LVI in AEG.
Open AccessLymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification
Adenocarcinoma of the gastroesophageal junction (AEG) is an aggressive cancer with rising incidence and poor long-term survival despite multimodal treatment. Reliable preoperative prognostic markers are lacking. Methods: The study is based on data from a prospectively maintained institutional database, which was retrospectively analyzed. In total, 211 patients were analyzed who underwent curative resection for AEG to evaluate the association of SII and LVI and their combined prognostic value. Results: LVI was present in 45% of patients and was significantly associated with higher median SII values compared to patients without LVI (943 vs. 652; p < 0.001). Both high SII and the presence of LVI were independently associated with worse overall survival (p < 0.001 for both). In patients treated with primary surgery (65%), the combined presence of high SII and LVI identified a subgroup with particularly poor prognosis (pseudo-R2 increased from 0.451 to 0.524; likelihood-ratio test p < 0.001). Among patients who received neoadjuvant therapy (NT) (35%), SII remained a strong prognostic factor (pseudo-R2 = 0.432), while LVI alone was not statistically significant (p = 0.135), and its addition to the SII model did not improve prognostic performance (p = 0.377). Conclusions: The combined assessment of SII and LVI may improve prognostic stratification in AEG, especially in patients undergoing upfront surgery. These findings suggest that combined assessment of SII and LVI enhances prognostic stratification, particularly in patients treated with upfront surgery, and may aid personalized treatment and follow-up planning in AEG. To the best of our knowledge, this is the first study investigating the association of SII and LVI in AEG.
- Open Access
Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration
FGF8, ALK, and EML4 have been identified as promising biomarkers in a number of malignancies. The aim of this study was to examine the prognostic role of FGF8, ALK, and EML4 in esophageal squamous cell carcinoma (ESCC). Methods: Consecutive patients with ESCC who underwent upfront resection were included in this study. ALK and EML4 gene status was evaluated by fluorescence in situ hybridization (FISH) using a triple-color break-apart single-fusion probe and a probe against 2p11. FGF8, ALK, and EML4 protein expression was determined by immunohistochemistry. Results: A total of 122 patients were included in this study. Multivariate analysis revealed that FGF8 overexpression is an independent negative prognostic factor for patients’ overall survival (OS) (p = 0.04). Furthermore, a significant correlation between the expression of FGF8, and ALK (p = 0.04) and EML4 (p = 0.01) alteration was found. Conclusions: FGF8 overexpression is an adverse independent prognostic factor in patients with upfront resected ESCC. Furthermore, FGF8 expression significantly correlates with ALK and EML4 amplification and may therefore qualify as a future therapeutic target.
Open AccessOverexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration
FGF8, ALK, and EML4 have been identified as promising biomarkers in a number of malignancies. The aim of this study was to examine the prognostic role of FGF8, ALK, and EML4 in esophageal squamous cell carcinoma (ESCC). Methods: Consecutive patients with ESCC who underwent upfront resection were included in this study. ALK and EML4 gene status was evaluated by fluorescence in situ hybridization (FISH) using a triple-color break-apart single-fusion probe and a probe against 2p11. FGF8, ALK, and EML4 protein expression was determined by immunohistochemistry. Results: A total of 122 patients were included in this study. Multivariate analysis revealed that FGF8 overexpression is an independent negative prognostic factor for patients’ overall survival (OS) (p = 0.04). Furthermore, a significant correlation between the expression of FGF8, and ALK (p = 0.04) and EML4 (p = 0.01) alteration was found. Conclusions: FGF8 overexpression is an adverse independent prognostic factor in patients with upfront resected ESCC. Furthermore, FGF8 expression significantly correlates with ALK and EML4 amplification and may therefore qualify as a future therapeutic target.